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Background: Although the current standard preoperative chemoradiotherapy (PCRT) for
stage II/III rectal cancer decreases the risk of local recurrence, it does not improve survival
and increases the likelihood of preoperative overtreatment, especially in patients without
circumferential resection margin (CRM) involvement.
Methods: Stage II/III rectal cancer without CRM involvement and lateral lymph node
metastasis was radiologically defined by preoperative magnetic resonance imaging (MRI).
Patients who received PCRT followed by total mesorectal excision (TME) (PCRT group)
and upfront surgery (US) with TME (US group) between 2010 and 2016 were analyzed.
We derived cohorts of PCRT group versus US group using propensity-score matching for
stage, age, and distance from the anal verge. Three-year relapse-free survival rate,
disease-free survival (DFS), and overall survival (OS) were compared between the two
groups.
Results: A total of 202 patients were analyzed after propensity score matching. There
were no differences in baseline characteristics. The median follow-up duration was 62
months (interquartile range, 46–87). There was no difference in the 3-year disease-free
survival rate between the PCRT and US groups (83 vs. 88%, respectively; p=0.326).
Likewise, there was no significant difference in the 3-year OS (89 vs. 91%, respectively;
p=0.466). The 3-year locoregional recurrence rates (3 vs. 2% with US, p=0.667) andORIGINAL RESEARCH
published: 18 January 2021
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Frontiers in Oncology | www.frontiersin.orgdistant metastasis rates (16 vs. 11%, p=0.428) were not significantly different between the
two groups. Time to completion of curative treatment was significantly shorter in the US
group (132 days) than in the PCRT group (225 days) (p<0.001).
Conclusion: Using MRI-guided selection for better risk stratification, US without
neoadjuvant therapy can be considered in early stage patients with good prognosis.
PCRT may not be required for all stage II/III rectal cancer patients, especially for the MRI-
proven intermediate-risk group (cT1-2/N1, cT3N0) without CRM involvement and lateral
lymph node metastasis. Further prospective studies are warranted.Keywords: stage II/III, rectal cancer, total mesorectal excision, upfront surgery, chemoradiotherapyINTRODUCTION
Colorectal cancer (CRC) is the third most commonly diagnosed
cancer worldwide and the second cause of cancer related death
(1). The incidence of CRC is rising globally due to increase in
western diet (2). Currently, the standard treatment for stage II/III
rectal cancer is preoperative chemoradiotherapy (PCRT)
followed by surgery and adjuvant chemotherapy (3). PCRT is
effective in reducing local recurrence and down staging locally
advanced rectal cancer (4, 5). However, it is associated with
complications such as bowel (6), anorectal (7), and sexual
dysfunctions (8, 9) and delay from surgical recovery (10).
Although many patients benefit from local control of PCRT,
there is still debate over whether it improves overall survival (11,
12). About one-third of patients relapse with metastasis despite
treatment with PRCT and surgery (13).
Currently, National Comprehensive Cancer Network (NCCN)
guidelines recommend preoperative chemoradiotherapy for tumors
that are 1) T3, any N with clear CRM and 2) T1-2, N1-2 (14). In
recent years, the incorporation of magnetic resonance imaging
(MRI) in the preoperative setting has helped in better identification
of tumor characteristics that dictate treatment strategies (15).
Identification of features such as negative CRM, substaging T3,
extramural venous invasion and nodal status in rectal cancer has
helped treatment decisions in rectal cancer. In addition, the
limitations of PRCT have led investigators to design trials that may
omit PRCT in treatment of rectal cancer. Both the MERCURY (16)
andOCUM (17) studies showed that rectalMRI could be used as an
indicator to predict prognosis prior to surgery, thereby adjusting
treatment according to patient’s prognosis. The QuickSilver study
further addressed this issue by selecting MRI-predicted good
prognosis subjects that resulted in a low rate of positive
circumferential resection margin (CRM) (18). This study suggested
thepossibility of omittingPCRT insubjectswith anegativeCRMand
no lateral lymph node metastasis in stage II/III rectal cancer.
The identification of subjects who do not need PCRT in an
important issue in stage II/III rectal cancer. If adequate local
control can be achieved by surgery alone, omitting PRCT may
save patients from unnecessary chemotherapy and radiotherapy,
thereby decreasing the time from diagnosis to surgery and
without the associated complications from PRCT. Whether
upfront surgical resection without PCRT is feasible for the
above-defined subset of patients warrants further evidence.2
In this study, we retrospectively selected MRI-proven
intermediate-risk group (cT1-2/N1, cT3N0) patients without
CRM involvement or lateral lymph node metastasis. The
patients either received PRCT followed by TME (PCRT group)
or underwent upfront radical surgery (US group). After selecting
patients using propensity score analysis, we assessed the
clinicopathological characteristics, disease free survival (DFS),
overall survival (OS), and cumulative incidence of local and
distant recurrence between the two groups. The primary
objective of our study was to evaluate the 3-year DFS and OS
between these two groups. Our hypothesis was that DFS and OS
of upfront surgical resection are non-inferior to those of PCRT.MATERIALS AND METHODS
Study Design and Population
This was a retrospective study of stage II and III rectal cancer
patients who received either PCRT followed by total mesorectal
excision (TME) or underwent upfront radical surgery in Yonsei
Cancer Center. Standardized rectal cancer MRI protocol was
used for assessment of patients initially diagnosed with rectal
cancer (18). Key inclusion criteria included (1) histologically
confirmed stage II/III rectal adenocarcinoma with distance from
anal verge ≤ 10 cm, (2) MRI predicted circumferential resection
margin (CRM) greater than 1mm away from primary tumor, (3)
extramural depth of invasion (EMD) ≤5mm, (4) absent
extramural venous invasion (EMVI), (5) without pelvic lymph
node involvement, (6) without distant metastasis, (7) surgery
with TME, and (6) 3-year surveillance period after surgical
resection. Patients with T1 and T2 tumors with N0 status, and
patients requiring intersphicteric resection or abdominal
perineal resection (APR) were excluded from the study.
The clinicopathologic variables such as age, gender,
tumor grade, preoperative and postoperative MRI, clinical
staging, types of surgery, pathologic staging, toxicity profiles of
radiotherapy, and patterns of recurrence were collected. Staging
was determined using the 8th edition of the American Joint
Committee on Cancer guideline of tumor, node, and metastasis
(TNM) classification (19). CRM negative was defined as distance
to the mesorectal fascia greater than 1 mm from the primary
tumor (18).January 2021 | Volume 10 | Article 609313
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minimize bias (20, 21). Covariates included 1) clinical T stage 2)
clinical N stage 3) primary location from the anal verge and 4)
carcinoembryonic antigen (CEA) levels. Patients with missing
data were excluded from the analysis.
This study was conducted in accordance with the Declaration
of Helsinki. All patients provided written informed consent. The
study was approved by institution review board of Yonsei Cancer
Center (IRB 4-2020-0209).
Treatment and Assessment
Baseline and follow up MRI were acquired on a 3.0-T system
(MAGNETOM TrioTim; Siemens, Erlangen, Germany), and T2-
weighted images of sagittal, axial, and oblique view were assessed
(22). Further details of MRI techniques are discussed in previous
protocols (23).
Patients diagnosed with stage II/III rectal cancer were either
treated with upfront radical surgery only or PCRT followed by
surgery. The 3-dimensional conformal radiotherapy (3D-CRT)
was given at 45 Gy in 25 fractions over the course of 5 weeks,
preoperatively for the PCRT group, and postoperatively for US
group. During treatment, the following chemotherapy agents
were given: intravenous 5-fluorouracil (425 mg/m2) and
leucovorin (20mg/m2) were given as bolus on weeks 1 and 5,
or capecitabine 1,650mg twice a day throughout radiation
treatment. Interim assessment after PCRT was assessed with
MRI for adaptation of surgical plan, and surgery was planned 6–
8 weeks after completion of PCRT. In the US group, MRI was
done at 4–6 weeks after surgery.
For both the PCRT and US group, patients were treated with
adjuvant chemotherapy regimen such as FOLFOX (bolus and
infused fluorouracil with oxaliplatin) and CAPOX (capecitabine
and oxaliplatin) over the course of 6 months. Patients treated with
FOLFOX were given oxaliplatin 85mg/m2 for 2 h with leucovorin
350mg intravenously, followed by bolus of fluorouracil 400mg/m2
on day 1 and infusion of fluorouracil 2,400mg/m2 over 2 days.
Treatment was repeated every 2 weeks with total of 12 cycles in 6
months. CAPOXwas given with 1,000mg/m2 of capecitabine twice
per day for the first 14 days, and intravenous oxaliplatin 85mg/m2
over 2 h on day 1. The cycle was repeated every 3 weeks with a total
of 8 cycles over 6 months.
Six weeks after surgery, patients who were candidates for
adjuvant chemotherapy and radiotherapy received treatment
accordingly. All patients followed up with computed
tomography (CT) scans and CEA levels every 3 months for the
first 2 years, and every 6 months for the next 3 years thereafter.
Follow up colonoscopy was done at 1 year, 3 years and 5 years
after surgery. Local recurrence was defined as tumor relapse
within pelvis and perineum. Distant metastasis was defined as
tumor recurrence outside locoregional area.
Outcomes
Primary endpoints were 3-year DFS and OS in patients of rectal
cancer with stage II/III disease who received either PCRT or
underwent upfront radical surgery. Secondary endpoint was
recurrence rate between two groups.Frontiers in Oncology | www.frontiersin.org 3Statistical Analysis
We analyzed data using Statistical Package for the Social Sciences
(SPSS) version 25 (IBM, Chicago, IL) and the statistical software
R (https://www.r-project.org, v3.5.0). Propensity score matching
was performed to control potential confounding bias (20). The
matching was constructed using clinical T stage, clinical N stage,
primary location from the anal verge and CEA levels using the
“MatchIt” R package. The nearest neighbor method was used
with a caliper of 0.20 (Supplementary Figures 1A, B). Further,
we conducted a sensitivity analysis for the matching estimate
using “rbounds” R package, suggested by Rosenbaum (23).
Briefly, sensitivity analysis for matched data evaluated the
magnitude of potential bias using the Wilcoxon signed rank
test. When gamma G (log odds of differential assignment to
treatment due to unobserved factors) = 1, it holds assuming
there is no hidden bias due to an unobserved confounder
(Supplementary Figure 1C).
The correlations between variables were analyzed using
Fischer’s exact test for categorical variables and sample t-test for
continuous variables. Kaplan Meier with log-rank test was used to
analyze survival difference between the two groups. Disease-free-
survival (DFS)wasdefinedas the time interval between surgery and
tumor recurrence or last follow-up. Overall survival (OS) was
defined as the time interval between the surgery and death or last
follow-up.RESULTS
Patient Characteristics
Between January 2010 to June 2016, a total of 354 patients were
diagnosed with rectal cancer in Yonsei Cancer Center. After
excluding patients who had metastatic sites (n=43), double
primary cancer (n=5), and incomplete data set due to follow
up loss (n=37), data of 269 patients [PCRT, n=160 (59%); US,
n=109(41%)] were collected. Since PRCT patients had relatively
poorer prognostic factors such as high CEA and advanced
clinical stage as compared to the US group, we used propensity
score to adjust baseline characteristics between the two groups.
After propensity score matching of 1:1 ratio, a total of 202
patients were selected for analysis with 101 patients from each
group (Figure 1). All of the patients in the PCRT group
completed planned cycles of pre-operative chemoradiotherapy
without dose modifications.
MRI-Based Tumor Characteristics and
Histopathological Tumor Staging
Preoperative clinicopathological characteristics such as age,
clinical stage, CEA level, and tumor location were well balanced
between the two groups (Table 1). Most of the patients underwent
lower anterior resection (LAR) [PCRT, n=96 (96%); US, n=96
(96%)]. Other surgical methods included ultralow anterior
resection [PCRT, n=5(5%); US, n=3(3%)], transanal endoscopic
operation (US, n=1) and total colectomy (US, n=1).
In the PRCT group, there was significant down staging of
postoperative pathologic stage (ypStage) after pre-operativeJanuary 2021 | Volume 10 | Article 609313
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had a complete response (pT0) (p=0.000) and 83 patients
(83%) with negative lymph nodes (p=0.001). Overall, PRCT
group had higher proportion of stage I (n=58, 58%, p=0.000)
and lower percentage of stage III (n=18, 18%) compared to the
US group of stage I (n=33, 33%) and stage III (n=39,
39%), respectively.
Overall, there was no difference in recurrence at 3-years
between the two groups [PRCT, n=17 (17%); US, n=12 (12%)]
(p=0.316). Patterns of recurrence were also similar between the
two groups, indicating that although PCRT group may have
lower TNM stages, it had no effect on local [PCRT, n=3 (3%); US,
n=0], distant [PCRT, n=13(13%); US, n=11(11%)] and
combined local and distant recurrence [PCRT, n=1(1%); US,
n=1(1%)] at 3 years (p=0.364). After TME, majority (n=83, 83%)
of the PRCT patients did not receive treatment while 56% of US
group required further treatment such as adjuvant
chemoradiotherapy (CRT) (n=32, 32%) and adjuvant
chemotherapy (n=24, 24%).
Disease Free Survival, Overall Survival,
and Local Recurrence Rate
At the data cut-off date of September 21, 2019, the median
follow-up duration was 62 months (interquartile range, 46–87
months). Seventeen (17%) patients in the PRCT group and 8
patients (8%) in the US group had died. There was no difference
in the 3-year DFS rate between PRCT group (83%) and US group
(88%) (p=0.328) (Figure 2). No statistical difference in overall
survival was seen between two groups; 3-year OS was 91 vs. 89%
in US and PCRT group, respectively (p=0.466). Likewise, there
was no difference in the rates of local and distant metastases. The
rates of locoregional recurrence and distant metastasis at 3 years
in PRCT and US groups were 3 vs. 2% (p=0.667) and 16 vs. 11%
(p=0.428), respectively (Figure 3).Frontiers in Oncology | www.frontiersin.org 4Toxicity Profile
Among the PCRT group, 73 patients (73%) experienced adverse
events of any grade (Table 2). The most common adverse events
related to CRT were fatigue (n=42, 42%), diarrhea (n=42, 42%),
and poor oral intake (n=41, 41%). In addition, fecal incontinence
and tenesmus were seen in 18 patients (18%) and 9 patients (9%),
respectively. The most common grade 3 adverse event was
diarrhea (n=16, 16%). Of note, 1 patient (1%) had anastomotic
leakage which required surgical intervention.
In the US group, 32 patients (32%) received adjuvant CRT,
and 26 (79%) experienced adverse events of any grade including
fatigue (n=16, 48%), diarrhea (n=11, 33%), and fecal
incontinence (n=5, 15%). Grade 3 adverse event was only seen
in diarrhea (n=5, 15%). Although the US group had higher
incidence of adverse events of any grade, there was less grade 3
adverse events, and adverse events were manageable with
supportive care. There were no adverse events of ≥ G4 or
death due to CRT complications in both groups.DISCUSSION
In our single center, retrospective study using propensity score
analysis, we assessed the 3-year DFS and OS of preoperative
chemotherapy followed by surgery versus upfront surgery in
MRI proven, CRM negative stage II and III rectal cancer. Our
study showed that although PCRT had significantly down-staged
from the earlier postoperative pathologic stage, there was no
difference in 3-year DFS, OS and cumulative incidence of local
and distant recurrence between PRCT and US group. In
addition, the retrospective analysis of adverse events due to
CRT reflect that US groups had manageable toxicity of mostly
grade 1–2. Compared to the PRCT group, the US group had less
grade 3 adverse events which led to hospitalization, and surgicalFIGURE 1 | Study scheme. PCRT, Preoperative chemoradiotherapy; US, Upfront surgery.January 2021 | Volume 10 | Article 609313
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Frontiers in Oncology | www.frontiersin.org 5intervention for anastomotic leakage. Taken together, the
oncologic outcomes of upfront-surgery group are comparable
to those of PRCT group. With MRI directed patient
stratification, it is possible for patients in intermediate-risk
group (cT1-2/N1, cT3N0) without CRM involvement and
lateral lymph node metastasis to omit PRCT, thereby avoiding
overtreatment and reducing treatment duration.
Previously, there have been conflicting reports about the role
of PCRT in locally advanced rectal cancer (5, 24–28). The Dutch
trial showed that PRCT reduced the rate of local recurrence but
had no impact on overall survival rate (26). Similarly, studies by
German Rectal Cancer Study Group and Medical Research
Council (MRC)-07 showed that although PRCT has a role in
improving local control, there was no impact in overall survival
(5, 24). Few studies have even pointed out that PCRT is
unnecessary and may possibly be an overtreatment for some
patients with stage II disease (27, 28).
Thereafter, several studies have proved that high-resolution
rectal MRI has optimized the selection of CRM negative patient
(16, 17). Good prognosis tumors treated with upfront surgery
resulted in 2–5% of positive CRM patients (18). Even with
upfront TME surgery alone, the 5-year local recurrences rates
were as low as 4.4% (29). These findings are encouraging since
patients without CRM involvement may selectively omit PCRT,
thereby avoiding unnecessary complications from radiotherapy,
save medical costs, and receive surgery without delay (30, 31).
Very few retrospective studies have addressed whether PCRT
is essential in locally advanced rectal cancer. In a study
comparing surgery alone and PRCT in recto-sigmoid
junction cancer, PRCT was associated with 5% improvement
of 5-year OS (32). However, that study included recto-sigmoid
colon cancer. In contrast to the distal tumors that respond more
favorably to PCRT, tumors located proximal from the anal verge
respond less to PCRT (26). Therefore, the results with improved
OS with PRCT in recto-sigmoid colon cancers must be
interpreted with caution. In another study, early T3 rectal
cancer patients who were either treated with surgery alone
versus PRCT showed that 5-year local recurrence rate was 2%
for both groups, and 5-year DFS were not statistically different
(87% in surgery alone versus 88% in PRCT group) (33). Recently,
a meta-analysis on total neoadjuvant therapy (TNT) addressed
that TNT increases pathological down staging compared with
surgery and adjuvant CRT (34). Despite higher rate of
pathological complete response (pCR) by 39% in the TNT
group, there was no difference in DFS and OS was noted
between two groups.
Similarly, our study results proved that there was no
difference 3-year OS between PRCT and US group. In
addition, there was no difference in 3-year DFS and incidence
of both local and distant recurrence between the two groups.
Whether PCRT is a prerequisite in stage II/II rectal cancer,
especially for MRI proven intermediate-risk group (cT1-2/N1,
cT3N0) without CRM involvement and lateral lymph node
metastasis, should be validated with prospective, randomized
controlled trials in the future.TABLE 1 | Baseline patient characteristics.
Characteristics PCRT Group US Group p value
No. (%) n = 101 n = 101
Age, years, Median (IQR)
< 70 55 (51–63) 57 (49–62) 0.87
≥ 70 73 (70–76) 74 (72–78)
Gender
Male 73 (73%) 65 (65%) 0.226
Female 28 (28%) 36 (36%)
CEA, ng/dl
< 5 64 (64%) 76 (76%) 0.067
≥ 5 37 (37%) 25 (25%)
Tumor location, from anal verge, cm
≤ 5 12 (12%) 12 (12%) 1
> 5 89 (89%) 89 (89%)
Tumor grade
WD 14 (14%) 9 (9%) *0.743
MD 83 (83%) 87 (87%)
PD 2 (2%) 3 (3%)
Unknown 2 (2%) 2 (2%)
MRI findings
cT stage
cT1, 2 15 (15%) 23 (23%) 0.132
cT3 86 (86%) 78 (78%)
cN stage
N0 28 (28%) 39 (39%) 0.182
N+ 73 (73%) 62 (62%)
pT category
pT0 23 (23%) 0 (0%) 0
pTis 2 (2%) 1 (1%)
pT1 7 (7%) 8 (8%)
pT2 35 (35%) 36 (36%)
pT3 34 (34%) 56 (56%)
pN category
pN0 83 (83%) 62 (62%) 0.001
pN1 14 (14%) 32 (32%)
pN2 4 (4%) 7 (7%)
pStage
Stage I, T1-T2, N0 58 (58%) 33 (33%) 0
Stage II, T3-4, N0 25 (25%) 29 (29%)
Stage III, any T, N1-
N2
18 (18%) 39 (39%)
Type of surgery
LAR 96 (96%) 96 (96%) *0.499
ULAR 5 (5%) 3 (3%)
Other surgery§ 0 (0%) 2 (2%)
Recurrence
No 84 (84%) 89 (89%) 0.316
Yes 17 (17%) 12 (12%)
Pattern of recurrence
Local recurrence 3 (3%) 0 (0%) *0.364
Distant 13 (13%) 11 (11%)
Local + Distant 1 (1%) 1 (1%)
Surgery (TME)
Complete 101 (100%) 101
(100%)
Incomplete 0 (0%) 0 (0%)§Patients who received with “Other surgery” include 1 transanal endoscopic operation,
1 total colectomy.
*Fisher’s exact test.
PCRT, preoperative chemoradiotherapy; US, upfront surgery; IQR, interquartile range;
CEA, carcinoembryonic antigen; WD, well differentiated; MD, moderately differentiated;
PD, poorly differentiated; MRI, magnetic resonance imaging; cT, clinical tumor; cN, clinical
node; pT, pathologic tumor; pN, pathologic node; pStage, pathologic stage; LAR, lower
anterior resection; ULAR, ultralow anterior resection; TME, total mesorectal excision.January 2021 | Volume 10 | Article 609313
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collected data retrospectively from a single center. Although we
used propensity score matching to minimize cofounding
covariates, variables such as physician’s choice for upfront
surgery or PCRT, and patients’ treatment preferences may
have inadvertently affected the allocation between two groups.
Second, only the data from our institution was collected. Larger
patient sampling from multi-centers in randomized controlledFrontiers in Oncology | www.frontiersin.org 6study (RCT) may provide additional information to clarify
whether PCRT may be selectively avoided.
In conclusion, omitting PRCT and treatment with upfront
surgery alone in CRM negative rectal cancer stage II/III patients
may be considered as future treatment options. To further validate
our retrospective results, a phase 2, randomized controlled trial of
upfront surgery versus PRCT followed by surgery is currently
ongoing (ClinicalTrials.gov, NCT02167321) (35).A B
FIGURE 3 | Cumulative incidence of (A) local recurrence and (B) distant recurrence. Abbreviation: CRT, Chemoradiotherapy.A B
FIGURE 2 | Kaplan-Meier survival curves for (A) disease free survival (DFS) and (B) overall survival (OS). Abbreviation: CRT, Chemoradiotherapy.January 2021 | Volume 10 | Article 609313
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